S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
NASDAQ:AXDX

Accelerate Diagnostics - AXDX Stock Forecast, Price & News

$2.15
+0.09 (+4.37%)
(As of 08/11/2022 04:34 PM ET)
Add
Compare
Today's Range
$2.07
$2.27
50-Day Range
$0.60
$2.13
52-Week Range
$0.50
$7.19
Volume
443,749 shs
Average Volume
682,706 shs
Market Capitalization
$149.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

Accelerate Diagnostics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
53.1% Downside
$1.00 Price Target
Short Interest
Bearish
10.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.62
Upright™ Environmental Score
News Sentiment
0.63mentions of Accelerate Diagnostics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$25,660 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.33) to ($1.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

1006th out of 1,112 stocks

Analytical Instruments Industry

26th out of 31 stocks

AXDX stock logo

About Accelerate Diagnostics (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Accelerate Diagnostics Stock Up 14.4 %

NASDAQ:AXDX traded up $0.26 during mid-day trading on Wednesday, reaching $2.06. 479,977 shares of the stock were exchanged, compared to its average volume of 684,260. The company has a 50 day simple moving average of $1.20 and a 200-day simple moving average of $1.52. The stock has a market capitalization of $143.50 million, a P/E ratio of -1.94 and a beta of 1.51. Accelerate Diagnostics has a 1 year low of $0.50 and a 1 year high of $7.19.

Accelerate Diagnostics (NASDAQ:AXDX - Get Rating) last released its quarterly earnings results on Monday, May 16th. The medical research company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.07. The firm had revenue of $2.96 million for the quarter, compared to analysts' expectations of $2.90 million. During the same quarter in the prior year, the business earned ($0.41) EPS. As a group, research analysts predict that Accelerate Diagnostics will post -1.33 EPS for the current year.

Wall Street Analysts Forecast Growth

AXDX has been the topic of several recent research reports. Craig Hallum cut their price target on Accelerate Diagnostics to $1.00 and set an "underperform" rating on the stock in a report on Tuesday, May 17th. StockNews.com downgraded Accelerate Diagnostics from a "hold" rating to a "sell" rating in a report on Saturday, June 4th.

Insider Activity

In other news, CEO Jack Phillips sold 28,198 shares of the firm's stock in a transaction that occurred on Wednesday, June 22nd. The stock was sold at an average price of $0.91, for a total value of $25,660.18. Following the completion of the sale, the chief executive officer now directly owns 242,035 shares of the company's stock, valued at approximately $220,251.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 42.20% of the company's stock.

Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Stock News Headlines

Accelerate Diagnostics Posts Smaller Q1 Loss
Accelerate Diagnostics Q1 2022 Earnings Preview
Earnings Preview For Accelerate Diagnostics
Earnings Outlook For Accelerate Diagnostics
See More Headlines
Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Company Calendar

Last Earnings
5/16/2022
Today
8/11/2022
Next Earnings (Confirmed)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXDX
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.00
High Stock Price Forecast
$1.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
-53.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-77,700,000.00
Net Margins
-555.47%
Pretax Margin
-555.12%

Debt

Sales & Book Value

Annual Sales
$11.78 million
Book Value
($0.57) per share

Miscellaneous

Free Float
40,264,000
Market Cap
$149.77 million
Optionable
Optionable
Beta
1.51














AXDX Stock - Frequently Asked Questions

Should I buy or sell Accelerate Diagnostics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXDX, but not buy additional shares or sell existing shares.
View AXDX analyst ratings
or view top-rated stocks.

What is Accelerate Diagnostics' stock price forecast for 2022?

2 Wall Street analysts have issued 12-month target prices for Accelerate Diagnostics' stock. Their AXDX share price forecasts range from $1.00 to $1.00. On average, they predict the company's share price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 54.8%.
View analysts price targets for AXDX
or view top-rated stocks among Wall Street analysts.

How have AXDX shares performed in 2022?

Accelerate Diagnostics' stock was trading at $5.22 at the beginning of the year. Since then, AXDX shares have decreased by 57.7% and is now trading at $2.21.
View the best growth stocks for 2022 here
.

When is Accelerate Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our AXDX earnings forecast
.

How can I listen to Accelerate Diagnostics' earnings call?

Accelerate Diagnostics will be holding an earnings conference call on Monday, August 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "5773022".

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced its earnings results on Monday, May, 16th. The medical research company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.07. The medical research company had revenue of $2.96 million for the quarter, compared to analyst estimates of $2.90 million. During the same quarter in the previous year, the business posted ($0.41) earnings per share.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Griffin Asset Management Inc. (5.72%), JPMorgan Chase & Co. (0.54%), Belpointe Asset Management LLC (0.50%), Allworth Financial LP (0.22%), UBS Group AG (0.06%) and Baird Financial Group Inc. (0.04%). Insiders that own company stock include Hany Massarany, Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends
.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $2.21.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics (NASDAQ:AXDX) has a market capitalization of $153.95 million and generates $11.78 million in revenue each year. The medical research company earns $-77,700,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

The company employs 220 workers across the globe.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The official website for the company is acceleratediagnostics.com. The medical research company can be reached via phone at (520) 365-3100, via email at investors@axdx.com, or via fax at 520-269-6580.

This page (NASDAQ:AXDX) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.